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 Functional gastrointestinal disorders (FGID) are classified based on reported 
symptoms, and there is an ongoing process to improve the phenotyping of these 
conditions. We have investigated the characteristics and overlap of FGID in a large 
cohort of patients and controls three years after acute giardiasis.  
 FGID following acute giardiasis have different characteristics and more overlap than 
sporadic FGID in the control group,  
 These results represent a significant addition to our knowledge about the epidemiology 





Irritable bowel syndrome (IBS) is a common complication following gastroenteritis, and a 
high prevalence of post-giardiasis IBS has previously been reported. This study aims to 
investigate the prevalence, adjusted relative risk (RRadj) and overlap of different functional 
gastrointestinal disorders (FGID) according to Rome III criteria following infection with 
Giardia lamblia.  
METHODS: 
All patients ≥ 18 years of age with verified giardiasis during an outbreak in 2004, and a 
control group matched by age and gender, were mailed a questionnaire three years later.  
KEY RESULTS: 
 The prevalence of functional dyspepsia (FD) was 25.9% in the exposed and 6.9% in the 
control group, RRadj: 3.9 (95% CI: 3.1–4.8). The prevalence of IBS was 47.9% and 14.3% 
respectively, RRadj: 3.4 (95% CI: 3.0–3.8). Prevalence of other gastrointestinal symptoms 
ranged from 70.0% vs. 39.7% for bloating (RRadj: 1.8) to 8.3% vs. 2.9% for nausea (RRadj: 
3.0) in the Giardia and the control group, respectively. Among individuals fulfilling criteria 
for IBS 44% in the exposed group and 29% in the control group also fulfilled criteria for FD. 
IBS subtypes based on Rome III criteria (stool consistency) showed poor agreement with 
subtypes based on frequency of bowel movements (Kappa-values: 0.17 and 0.27). 
CONCLUSIONS & INFERENCES: 
There were high prevalences and RRs of IBS, FD and other gastrointestinal symptoms 
following acute giardiasis, and a high degree of overlap between the disorders. The agreement 
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between different IBS subtype criteria varied, and there were also differences between the 
exposed and control group. 
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Functional gastrointestinal disorders (FGIDs) are widespread in the population and in clinical 
practice (1, 2). The most common and widely investigated disorder is irritable bowel 
syndrome (IBS) (3), but functional dyspepsia (FD) and other conditions are also common (4, 
5). The classification of these disorders has been revised on several occasions, reflecting the 
challenges in optimizing its usefulness for research and clinical practice (6). The current 
Rome III-criteria have also been criticized for poor validity, insufficient ability to discriminate 
FGID from organic disease, and limited agreement of the populations identified compared 
with previous criteria, and the process to reach a better set of criteria continues (7-9). 
The Rome III criteria define 28 different FGIDs in adults (10), and it has proven difficult to 
identify features and mechanisms that are unique to each diagnosis. There is considerable 
overlap in the prevalence of IBS and FD, and it has been suggested that the two conditions 
share some pathophysiological pathways (11, 12). Furthermore, longitudinal studies have 
demonstrated that patients with chronic gastrointestinal symptoms that meet criteria for a 
specific FGID at one time may later receive a different diagnosis due to fluctuations in 
symptoms (13, 14). 
IBS is often preceded by and considered a complication of infectious gastroenteritis (15). 
Increased risk of other FGIDs, like FD, has also been demonstrated after outbreaks of 
gastroenteritis (16). Given the important role of infections in the development of FGID, 
outbreaks provide good opportunities to increase our knowledge about these conditions.  
In the city of Bergen, Norway, there was a large outbreak of gastroenteritis caused by the 
parasite Giardia lamblia in 2004 (17). Giardia is widespread around the globe, and in several 
regions giardiasis is endemic, especially in areas where hygiene and water sanitation is poor. 
In Europe and North America Giardia is a commonly identified pathogen in waterborne 
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outbreaks of disease (18). During the outbreak in Bergen, 2 500 patients were treated for 
giardiasis, and 1 252 had a laboratory confirmed diagnosis (19). This was the first outbreak of 
such magnitude in Norway, and the well-defined exposure gives a unique opportunity to study 
the epidemiology of FGIDs following infection with an identified pathogen. We have 
previously reported a strong association between acute giardiasis and both IBS and chronic 
fatigue three years after the outbreak (19).  
The aim of this study was to investigate and report the prevalence, overlap and associations of 
FD, IBS and other GI symptoms in patients three years after acute giardiasis compared to that 
of a control group, and to explore the agreement of subtyping IBS based on stool consistency 




The data were collected in 2007 from a cohort of 1252 patients with acute giardiasis in 2004 
and 3594 controls, matched by age and gender, and who were not ill during the outbreak. We 
have previously reported the prevalence of chronic fatigue and IBS in the whole cohort (19). 
The present study was restricted to adults above the age of 18, including 1184 participants 
with previous giardiasis and 3380 controls.  All participants were mailed a questionnaire three 
years after the outbreak. Non-respondents were mailed again one month later.  
Variables 
The main outcome variables are FD and IBS with subgroups according to Rome III criteria 
(10). The questions from the Rome III Diagnostic Questionnaire (20) were translated into 
Norwegian according to a standardized procedure (19). We also recorded the outcomes 
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nausea, bloating, diarrhea, constipation and foul smelling stools/flatulence. We included the 
demographic variables gender, age (categorized into 20-years groups), marital status (four 
categories), educational level (three categories), employment status (eight categories, reduced 
to four in the analyses) and whether the person had been a student during the outbreak. 
Functional dyspepsia 
The Rome III diagnosis of FD is based on presence of symptoms related to the upper 
abdomen (postprandial fullness, early satiation and epigastric pain or burning) and exclusion 
of pathology that may explain the symptoms (21). The design of this study did not include 
investigation of patients, but in order to reduce misclassification we asked the participants to 
name any esophageal or gastric disorder diagnosed by a physician within the previous three 
years. A list of disorders defined to explain the symptoms, together with a description of the 
process to reach the decision, is provided as supplementary material.  
Irritable bowel syndrome 
A diagnosis of IBS is made when there is recurrent abdominal pain or discomfort at least 
three days per month in the last three months, and associated with at least two of three criteria 
related to defecation (onset associated with a change in frequency or consistency of stool, or 
improvement with defecation) (22). The Rome III criteria divide IBS into four subgroups 
based on stool consistency: “IBS with diarrhea” (loose or watery stools at ≥ 25% of bowel 
movements, and hard or lumpy stools at < 25 % of bowel movements) (IBS-D), “IBS with 
constipation” (hard or lumpy stools at ≥ 25 % of bowel movements, and loose or watery 
stools at < 25% of bowel movements) (IBS-C), “mixed IBS” (both loose/watery stools and 
hard/lumpy stools each at ≥ 25% of bowel movements) (IBS-M), and unsubtyped IBS 
(without abnormality of stool consistency to meet criteria for the others) (IBS-U). The 
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previous Rome II criteria also included criteria on straining/urgency during bowel movements 
and frequency of bowel movements for subtyping IBS (23). We didn’t have information on 
straining/urgency, but for further exploration of the characteristic of IBS in the two groups we 
also subdivided IBS according to frequency of bowel movements. “Frequent bowel 
movements” is defined as four or more bowel movements a day at least “sometimes”, and 
“infrequent bowel movements” as fewer than three bowel movements a week at least 
“sometimes”. Finally we subtyped IBS approximated to Rome II criteria (without data on 
straining/urgency). Diarrhea predominant IBS (d-IBS) is defined as: i) either frequent bowel 
movements and loose stools, or both, in the absence of both infrequent bowel movements and 
hard stools, or ii) both frequent bowel movements and loose stools in the presence of 
infrequent bowel movements. Constipation predominant IBS (c-IBS) is defined as: i) either 
infrequent bowel movements or hard stools, or both, in the absence of both frequent bowel 
movements and loose stools, or ii) both infrequent bowel movements and hard stools in the 
presence of either infrequent bowel movements and loose stools. Patients not fulfilling the 
criteria for d-IBS or c-IBS were categorized as having alternating or mixed IBS (a-IBS).  
Other functional gastrointestinal symptoms 
For the variables “bloating”, “nausea”, “diarrhea” and “constipation” we used questions from 
the Rome III Questionnaire. We did not ask about duration of these symptoms and therefore 
the variables are not identical to disorders defined by the Rome III criteria, as they require that 
the symptoms have been present for the last six months. Not entering these questions was a 
deliberate choice to limit the size of the questionnaire and make it feasible for this kind of 
study. “Bloating” is defined as having this symptom at least 2-3 days a month, and this is the 
same frequency that is used for “functional bloating” (22). Bloating more often than one day a 
week we describe as “severe bloating”. “Nausea” is defined as reporting nausea more than 
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once a week, the same as in “chronic idiopathic nausea” (21). “Diarrhea” is defined as loose 
or watery stools ≥ 75% of bowel movements and four or more bowel movements at least 
“sometimes”. The Rome III criteria for “functional diarrhea” require that IBS is not present, 
but since we wanted to look at overlap we didn’t apply this criterion. “Constipation” is 
defined as fewer than three defecations a week at least “often”.  
We included “foul-smelling stools or flatulence” as a variable because this is a symptom that 
several patients complained about during the outbreak, and asked how often, within the last 
three months, foul smell from stool or flatus affected activities of daily living (for instance 
avoiding social contact). In the manner of the Rome III Questionnaire there was an option of 
seven graded responses, and a response of “one day a week” or more often was defined as a 
positive response. 
Analyses and statistical methods 
Non-respondents were excluded for all analyses, as were pregnant participants. Participants 
with missing data were excluded from the analyses involving that particular variable.  
Association in 2×k tables was tested by Pearson’s chi²-test. Results are reported as relative 
risks (RR) with 95% confidence intervals (CI). Continuous variable means were compared 
using Gosset’s t test (24). The outcome variables were analyzed separately with respect to the 
risk factors and possible interactions using multiple logistic regression producing adjusted 
odds ratios (OR) with 95% CI (25), which were converted to RRs and corresponding CIs by 
the method of Zhang and Yu (26). Effect modification was tested by the Breslow-Day test for 
homogeneity of ORs after stratification. Confounding was evaluated by use of the Mantel-
Haenszel common OR and multiple logistic regression analyses, and variables found to be 
confounders were then controlled for by multiple logistic regression.  
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Agreement between IBS subtypes was tested using the Kappa statistic (κ), with 95% CI. A κ-
value of 1 implies perfect agreement, values > 0.8 indicate very good agreement, 0.61-0.8 
good agreement, 0.41-0.6 moderate agreement, 0.21-0.4 fair agreement, and < 0.21 very poor 
agreement (27). When analyzing agreement between Rome III and Rome II criteria we 
combined IBS-M and IBS-U, and compared the prevalence to that of a-IBS. 
Concordance rates, the proportions of patients belonging to the same or comparable subtypes 
by different classifications (IBS-D and IBS with frequent bowel movements, IBS-C and IBS 
with infrequent bowel movements, and Rome III with Rome II subtype) were calculated. 
Level of statistical significance was set at 0.05, and all tests were two-sided. All analyses 
were done using IBM SPSS Statistics version 23.  
Ethical aspects 
This study has been approved by the Regional Committee for Medical and Health Research 
Ethics (project 150.07), and by the Ombudsman for Privacy in Research, Norwegian Social 
Science Data Services (project 17014). 
 
RESULTS 
The response rates were 66% (781/1184) among exposed patients and 33% (1099/3380) 
among controls. Respondents were older than non-respondents (37.1 vs. 34.6 years, p < 
0.001) and the proportion of females was higher (66.4% vs. 57.4%, p < 0.001). Four controls 
were excluded because they reported having had giardiasis verified by a physician during the 
outbreak, and 64 female participants were excluded because they were pregnant, leaving 749 
exposed and 1063 controls for analyses. Characteristics of included participants are shown in 
table 1.  
Wensaas 13 
 
Irritable bowel syndrome and functional dyspepsia 
The prevalence of IBS in the whole cohort has been reported previously (19). The prevalence 
of IBS among the adults included in this study was 47.9% (339/707) in the exposed and 
14.3% (149/1042) in the control group, with an adjusted RR of 3.4 (95% CI: 3.0–3.8). The 
prevalence of FD was 25.9% (189/730) in the exposed and 6.9% (72/1049) in the control 
group, corresponding to an adjusted RR of 3.9 (95% CI: 3.1–4.8) for having FD three years 
after the outbreak for the exposed compared to the controls (table 2). The majority with FD 
also fulfilled the criteria for IBS. The prevalence of FD without concomitant IBS was 3.8% in 
the Giardia group and 2.5% in the control group, and the proportion of patients with FD that 
also had IBS was 85% and 62%, respectively in the two groups (tables 3 and 4).  
Other functional gastrointestinal disorders and symptoms 
Prevalences of other gastrointestinal symptoms are also shown in table 2. The prevalences of 
bloating, diarrhea, nausea and foul smelling stools were significantly higher in the exposed 
group, whereas the prevalence of constipation was similar in the two groups. The proportion 
of participants with these disorders that also had IBS ranged from 63% (bloating) to 88% 
(nausea) in the Giardia group, and from 28% (constipation) to 62% (functional dyspepsia) in 
the control group. The total overlap between the different FGID and symptoms in patients 
with complete datasets (and excluding pregnant participants) are shown for the Giardia-
exposed in table 3 and the controls in table 4. 
Subtyping IBS 
Both among the exposed and the controls IBS-D and IBS-M were most prevalent, but there 
were differences between the two groups. The proportion with IBS-D and IBS-M was higher 
and the proportion with IBS-C was lower among the exposed than among the controls (table 
Wensaas 14 
 
5). This subtyping is based on stool consistency, and the observed differences between the 
groups were results of a larger proportion of individuals with IBS having loose stools in the 
exposed group compared to the controls. The proportion with hard stools was similar in the 
two groups (table 5), and the higher proportion of IBS-C among controls was due to less 
participants also having loose stools and thereby fulfilling criteria for IBS-M.  
In the analysis of IBS subtyped by stool frequency, based on the presence of “frequent” or 
“infrequent” bowel movements, there was a significantly higher proportion of “IBS with 
frequent bowel movements” in the Giardia-group, and of “IBS with infrequent bowel 
movements” in the control group (table 5). This corresponded with the finding that among 
Giardia exposed with IBS the prevalence of “frequent bowel movements at least sometimes” 
was significantly higher compared to controls with IBS (69.9% vs. 47.7%, p < 0.001), and 
that the prevalence of “infrequent bowel movements at least sometimes” was significantly 
lower among Giardia exposed compared to controls with IBS (13.9% vs. 24.2%, p = 0.005).  
The agreement between subtyping IBS based on stool consistency according to Rome III 
criteria and the alternative subtyping based on frequency of bowel movements was very poor 
among the exposed (κ = 0.17) (table 6) and fair among the controls (κ = 0.27) (table 7), but 
the 95% CI for the κ-values overlap (0.11–0.23 vs. 0.18–0.36). In the subtyping according to 
Rome III criteria 46% of the Giardia-exposed IBS-patients reported both hard and loose 
stools fulfilling criteria for IBS-M, whereas in the alternative subtyping only 7% reported 
both frequent and infrequent bowel movements. Only 6% were classified with IBS-U 
according to Rome III criteria, but in the alternative subtyping 24% reported no abnormality 
in frequency of bowel movements sufficient to subtype them.  
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The agreement between subtyping based on Rome III and Rome II criteria was different in the 
two groups. It was very good in the Giardia group (κ = 0.86, 95% CI: 0.81–0.91) (table 8), 
and good in the control group (κ = 0.71, 95% CI: 0.61–0.80) (table 9). 
Gender differences 
There were significant gender differences in the prevalence of IBS, but gender was not an 
effect modifier. We have already reported this in the whole cohort (19), and in this study in 
adults the prevalence wa 51.4% in females and 41.7% in males in the exposed group (p = 
0.013), and 16.3% and 10.6%, respectively, in the control group (p = 0.012). For FD there 
were no gender differences in the prevalence neither in the exposed group (27.7% in females 
vs. 22.5% in males, p = 0.131) nor in the control group (7.3% vs. 6.0%, p = 0.414).   
 
DISCUSSION 
There were three main results in this paper: First, we found a high prevalence and RR of FD 
three years after acute giardiasis, as well as IBS which we have shown earlier (19), and other 
gastrointestinal symptoms. Post-giardiasis IBS was characterized by more loose stools and 
frequent bowel movements than sporadic IBS. Second, there was a high degree of overlap 
between IBS and other FGID, and this was more prominent in the Giardia group than among 
controls. Third, the agreement between IBS subtypes based on stool consistency according to 
Rome III criteria and frequency of bowel movements was only fair or very poor. When 
combining these characteristics according to Rome II criteria the agreement was better, and 




Strengths and weaknesses 
The outbreak of giardiasis in Bergen was well defined with a large population exposed to a 
verified pathogen for a restricted time period. It was one of the largest Giardia outbreaks 
described in the scientific literature, and the high number of infected individuals offers the 
opportunity to study the consequences in greater depth. An outbreak like this was not 
anticipated and the research protocol had to be set up at a time where the major focus was on 
managing the outbreak. The three year time gap after the acute infection made any data on 
previous FGID unreliable because of potential recall bias. Also, defining incident cases is 
difficult since IBS and other FGID are prevalent and post-giardiasis cases might manifest with 
aggravated or new symptoms. We did not attempt to give the incidence of post-giardiasis 
FGID, instead we included a control group and compared prevalences in the two groups. 
The response rates are comparable to those observed in similar studies (28, 29), but the 
response rate of 33% in the control group is still low and introduces a risk of bias. However, 
the prevalence of IBS in this group was similar to what has been found earlier in the general 
Norwegian population (30). The exposure to acute giardiasis during the outbreak may have 
led to increased awareness and a tendency towards reporting more gastrointestinal symptoms 
in the period to follow, but we did not find it plausible that this should explain a substantial 
proportion of the high prevalence of post-giardiasis complications, something that had not 
been described earlier and therefore was not anticipated (19). A key objective of this study 
was to explore the pattern of symptoms in affected individuals, and this should be less 
influenced by this kind of bias. 
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Ideally, persistent infection should be ruled out as chronic giardiasis may give FGID-like 
symptoms (31). The design of the study did not make this possible, but other studies have not 
found evidence for chronic infection in this population (32-34). 
Interpretation 
There was a higher prevalence of all outcomes except constipation in the exposed group 
compared to controls. This shows that the long term symptoms after giardiasis are not 
restricted to IBS, which is in line with the findings after outbreaks of gastroenteritis caused by 
Salmonella (28) and campylobacter/Enterohemorrhagic E. coli (EHEC) (35), and in a 
systematic review that documents increased risk of FD after acute gastroenteritis (16). 
There was substantial overlap between the different FGIDs in both groups, but the overlap 
between IBS and other FGIDs was more prominent in the exposed group suggesting that IBS-
criteria more precisely cover a common post-infectious condition, and that the abdominal 
symptoms and possible mechanisms behind them are more diverse in sporadic IBS. 
In addition to IBS and FD, where the main symptom by definition is pain or discomfort, the 
most prevalent manifestations of post-giardiasis FGID were looser stools and more frequent 
bowel movements. These features, especially stool consistency, but also frequency of bowel 
movements, have been shown to be associated with colonic transit time (36). The prevalence 
of patients reporting loose stools was high in the exposed group and significantly more 
patients had IBS-D and IBS-M compared to the controls. The higher proportion of IBS-C 
among controls was actually not explained by higher prevalence of hard stools, but by a lower 




The challenges related to subtyping IBS was addressed in the revision leading up to the 
current Rome III criteria (22, 37). One result of the revision was that the criteria were 
simplified, and the items related to frequency of bowel movements and straining/urgency 
were abandoned. Several groups have compared the subtype distribution of IBS based on 
Rome II and Rome III criteria (38-41), but none of these have reported the actual prevalence 
of different frequencies of bowel movements. In the current study we found good agreement 
between subtypes classified by Rome II and Rome III criteria, but the agreement was fair or 
poor when comparing stool consistency and frequency of bowel movements. These findings 
could have implications for the understanding of IBS and for possible treatments, something 
that is supported by the fact that the U.S. Food and Drug Administration calls for change in 
stool consistency for clinical evaluation of drugs for treatment in IBS-D, but recommends 
frequency of bowel movements in IBS-C (42).  
IBS is a chronic condition and classification has relied on patient retrospectively reporting 
prevalence of bowel movements and stool form. It has been shown that this correlates poorly 
with the findings when using a stool diary (38-41), but a couple of issues are still unclear. We 
know that agreement is poor for stool consistency, since the studies report Rome III subtypes 
that are based on this characteristic, but we don’t know how the agreement is for frequency of 
bowel movements. Further, the use of a stool diary covers a short period of time, typically 14 
days, while retrospective questionnaires focus on the last three months. If the questionnaires 
covered the same short period they are likely to produce results with better agreement. It 
could also be that a retrospective account of symptoms over a period of three months gives a 
more precise description of the chronic condition. The repeated use of stool diaries in the 
same patients have demonstrated that IBS subtypes change in more than 50% of patients 
within one year (38).  
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The results presented in this study differ markedly from other studies comparing 
classifications of IBS subtypes, and this emphasizes that caution should be made when 
interpreting data on symptoms patterns in IBS. We recruited patients that had suffered acute 
giardiasis three years earlier and not because they had gastrointestinal symptoms. Our focus 
was on post-infectious IBS, and cases were defined based on Rome III criteria. Other studies 
have included patients seen in gastroenterological clinics and as a result there could be a 
selection of symptom patterns in these populations with sporadic IBS, and also these studies 
defined IBS by Rome II criteria (38-41).    
Generalizability 
We have shown a high risk of different FGIDs and gastrointestinal symptoms after acute 
giardiasis. This study was performed in a population with verified giardiasis in an area where 
Giardia is rare; hence, we have made the assumption that most participants were previously 
unexposed. The burden of disease caused by giardiasis is much larger where the parasite is 
endemic, but there the population is exposed at a younger age and the clinical course and 
possible complications may differ. Further research on giardiasis in endemic areas is needed 
to get a better understanding of the impact of the disease there. Increased risk of IBS has also 
been shown after bacterial (28, 29, 43) and viral (44) gastroenteritis, and our findings add to 
the knowledge of post-infectious FGIDs in general. The differences between the exposed and 
the control group suggest that post-infectious FGIDs differ from sporadic FGIDs, and this 
should have implications for future research on epidemiology, mechanisms and possibly 
treatment.  
The pronounced overlap between different FGIDs, the differences between FGIDs in the two 
groups, and the challenges shown when subtyping IBS, are all aspects that should be 




An open grant from the Municipality of Bergen covered the cost for production and mailing 
of the questionnaire and for the services delivered by Statistics Norway. Knut-Arne Wensaas 
was partly funded by the Norwegian Medical Association's Funds for Research in General 
Practice. All researchers are independent from the sponsors. The sponsors had no role in study 
design, in collection, analysis and interpretation of data, or in the writing of the manuscript. 
DISCLOSURE 
The authors have no competing interests. 
AUTHOR CONTRIBUTION 
KAW contributed to the study concept and design of the study, acquisition, analysis and 
interpretation of data, and drafted the manuscript. KH, NL and KM contributed to the study 
concept and design, acquisition of data, and to critical revision of the manuscript for 
important intellectual content. GEE contributed to the analysis and interpretation of data. TH 
contributed to the study concept and design, and to critical revision of the manuscript for 
important intellectual content. GR contributed to the study concept and design, acquisition of 
data, to critical revision of the manuscript for important intellectual content, obtaining 






1. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, 
Janssens J et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, 
sociodemography, and health impact. Dig Dis Sci. 1993;38:1569-80. 
2. Koloski NA, Talley NJ, Boyce PM. Epidemiology and health care seeking in the functional GI 
disorders: a population-based study. Am J Gastroenterol. 2002;97:2290-9. 
3. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D et al. 
Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 
2007;56:1770-98. 
4. El-Serag HB, Talley NJ. Systemic review: the prevalence and clinical course of functional 
dyspepsia. Aliment Pharmacol Ther. 2004;19:643-54. 
5. Tuteja AK, Talley NJ, Joos SK, Tolman KG, Hickam DH. Abdominal bloating in employed adults: 
prevalence, risk factors, and association with other bowel disorders. Am J Gastroenterol. 
2008;103:1241-8. 
6. Thompson WG. The road to rome. Gastroenterology. 2006;130:1552-6. 
7. Dang J, Ardila-Hani A, Amichai MM, Chua K, Pimentel M. Systematic review of diagnostic 
criteria for IBS demonstrates poor validity and utilization of Rome III. Neurogastroenterol Motil. 
2012;24:853-60. 
8. Ford A, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P. Validation of the 
Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology. 
2103;145:1262-70. 
9. van Kerkhoven LA, Laheij RJ, Meineche-Schmidt V, Veldhuyzen-van Zanten SJ, de Wit NJ, 
Jansen JB. Functional dyspepsia: not all roads seem to lead to rome. J Clin Gastroenterol. 
2009;43:118-22. 
10. Drossman DA. The functional gastrointestinal disorders and the Rome III process. 
Gastroenterology. 2006;130:1377-90. 
11. Van Oudenhove L, Vandenberghe J, Vos R, Holvoet L, Tack J. Factors associated with co-
morbid irritable bowel syndrome and chronic fatigue-like symptoms in functional dyspepsia. 
Neurogastroenterol Motil. 2011;23:524-e202. 
12. Spiller R. Postinfectious functional dyspepsia and postinfectious irritable bowel syndrome: 
different symptoms but similar risk factors. Gastroenterology. 2010;138:1660-3. 
13. Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. Fluctuation of gastrointestinal 
symptoms in the community: a 10-year longitudinal follow-up study. Aliment Pharmacol Ther. 
2008;28:1013-20. 
14. Olafsdottir LB, Gudjonsson H, Jonsdottir HH, Bjornsson E, Thjodleifsson B. Natural history of 
functional gastrointestinal disorders: comparison of two longitudinal population-based studies. Dig 
Liver Dis. 2012;44:211-7. 
15. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 
2009;136:1979-88. 
16. Pike BL, Porter CK, Sorrell TJ, Riddle MS. Acute gastroenteritis and the risk of functional 
dyspepsia: a systematic review and meta-analysis. Am J Gastroenterol. 2013;108:1558-63. 
17. Nygard K, Schimmer B, Sobstad O, Walde A, Tveit I, Langeland N, Hausken T, Aavitsland P. A 
large community outbreak of waterborne giardiasis - delayed detection in a non-endemic urban area. 
BMC Public Health. 2006;6:141. 
18. Farthing MJ. Giardiasis. Gastroenterology clinics of North America. 1996;25:493-515. 
19. Wensaas KA, Langeland N, Hanevik K, Morch K, Eide GE, Rortveit G. Irritable bowel syndrome 
and chronic fatigue 3 years after acute giardiasis: historic cohort study. Gut. 2012;61:214-91. 
20. Rome III Diagnostic Questionnaire for the Adult Functional GI Disorders. [cited 2011 April 4]. 
Available from: http://www.romecriteria.org/pdfs/AdultFunctGIQ.pdf. 
Wensaas 22 
 
21. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, Stanghellini V. Functional 
gastroduodenal disorders. Gastroenterology. 2006;130:1466-79. 
22. Longstreth GF, Thompson WG, Chey WD, Houghton L, Mearin F, Spiller RC. Functional bowel 
disorders. Gastroenterology. 2006;130:1480-91. 
23.  Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. 
Functional bowel disorders and functional abdominal pain. Gut 1999;45 Suppl 2:Ii43-7 
24. Student. The probable error of a mean. Biometrika 1908;VI:1-25. 
25. Kleinbaum DG, Klein M. Logistic Regression. 2nd ed. New York: Springer; 2002. 
26. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort 
studies of common outcomes. JAMA. 1998;280:1690-1. 
27. Altman DG. Practical statistics for medical research, 1st ed. Florida: Chapman & Hall/CRC, 
1991.  
28. Mearin F, Perez-Oliveras M, Perello A, Vinyet J, Ibanez A, Coderch J, Perona M. Dyspepsia and 
irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort 
study. Gastroenterology. 2005;129:98-104. 
29. Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM. Incidence and 
epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. 
Gastroenterology. 2006;131:445-50. 
30. Vandvik PO, Lydersen S, Farup PG. Prevalence, comorbidity and impact of irritable bowel 
syndrome in Norway. Scand J Gastroenterol. 2006;41:650-6. 
31. Stark D, van Hal S, Marriott D, Ellis J, Harkness J. Irritable bowel syndrome: a review on the 
role of intestinal protozoa and the importance of their detection and diagnosis. Int J Parasitol. 
2007;37:11-20. 
32. Wensaas KA, Langeland N, Rortveit G. Post-infectious gastrointestinal symptoms after acute 
Giardiasis. A 1-year follow-up in general practice. Fam Pract. 2010;27:255-9. 
33. Mellingen KM, Midtun A, Hanevik K, Eide GE, Sobstad O, Langeland N. Post epidemic 
giardiasis and gastrointestinal symptoms among preschool children in Bergen, Norway. A cross-
sectional study. BMC Public Health. 2010;10:163. 
34. Morch K, Hanevik K, Robertson LJ, Strand EA, Langeland N. Treatment-ladder and genetic 
characterisation of parasites in refractory giardiasis after an outbreak in Norway. J Infect. 
2008;56:268-73. 
35. Ford AC, Thabane M, Collins SM, Moayyedi P, Garg AX, Clark WF, Marshall JK. Prevalence of 
uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort 
study. Gastroenterology. 2010;138:1727-36. 
36. Tornblom H, Van Oudenhove L, Sadik R, Abrahamsson H, Tack J, Simren M. Colonic transit 
time and IBS symptoms: what's the link? Am J Gastroenterol. 2012;107:754-60. 
37. Longstreth GF. Definition and classification of irritable bowel syndrome: current consensus 
and controversies. Gastroenterol Clin North Am 2005;34:173-87. 
38. Garrigues V, Mearin F, Badia X, Balboa A, Benavent J, Caballero A, Dominguez E, Diaz-Rubio 
M et al. Change over time of bowel habit in irritable bowel syndrome: a prospective, observational, 
1-year follow-up study (RITMO study). Aliment Pharmacol Ther 2007;25:323-32. 
39. Ersryd A, Posserud I, Abrahamsson H, Simren M. Subtyping the irritable bowel syndrome by 
predominant bowel habit: Rome II versus Rome III. Aliment Pharmacol Ther 2007;26:953-61. 
40. Dorn SD, Morris CB, Hu Y, Toner BB, Diamant N, Whitehead WE, Bangdiwala SI, Drossman DA. 
Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar. J Clin 
Gastroenterol 2009;43:214-20. 
41. Engsbro AL, Simren M, Bytzer P. The Rome II and Rome III criteria identify the same subtype-
populations in irritable bowel syndrome: agreement depends on the method used for symptom 
report. Neurogastroenterol Motil 2012;24:604-11. 
Wensaas 23 
 
42. U.S. Department of Health and Human Services, Food and Drug Administration, Center for 
Drug Evaluation and Research (CDER). Guidance for Industry. Irritable Bowel Syndrome — Clinical 
Evaluation of Drugs for Treatment. Available at: 
http://www.fda.gov/downloads/Drugs/Guidances//UCM205269.pdf. [cited 2015 January 28]. 
43. Ji S, Park H, Lee D, Song YK, Choi JP, Lee SI. Post-infectious irritable bowel syndrome in 
patients with Shigella infection. J Gastroenterol Hepatol. 2005;20:381-6. 
44. Zanini B, Ricci C, Bandera F, Caselani F, Magni A, Laronga Am, Lanzini A. Incidence of post-
infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral 





Table 1. Characteristics of a group of individuals exposed to Giardia infection during 
an outbreak three years earlier and a control group that did not contract the infection. 
Characteristics 
Exposed 
(N = 749) 
 Controls 
(N = 1063) p value 
Gender, n (%) 
Male 259  (34.6) 372 (35.0) 
0.855* 
Female 490  (65.5) 691 (65.0) 
Age 
Mean, (range) 37.4 (19-94) 37.2 (19-89) 0.732† 
Age 19–39, n (%) 497 (66.4) 707 (66.5) 
0.221* 
Age 40–59, n (%) 187 (25.0) 276 (26.0) 
Age 60–79, n (%) 56   (7.5) 76   (7.3) 
Age 80–99, n (%) 9   (1.2) 4   (0.4) 
Marital status, n (%) 
Single 240 (32.2) 263 (24.8) 
0.004* 
Married 464 (62.2) 747 (70.3) 
Divorced 33   (4.4) 41   (3.9) 
Widowed 9   (1.2) 11   (1.0) 
Education, highest level, n (%) 
Primary school 23   (3.1) 44   (4.2) 
0.001* Secondary school 153 (20.8) 293 (27.8) 
University 559 (76.1) 717 (68.0) 
Employment status, n (%) 
Worker 548 (73.4) 849 (80.2) 
< 0.001* 
Student, n (%) 110 (14.7) 99   (9.4) 
Unemployed/retired 68   (9.1) 95   (9.0) 
Other 21   (2.7) 15   (1.4) 
Student during the outbreak, n (%) 
Yes 271 (36.7) 255 (24.3) 
< 0.001* 
No 468 (63.3) 794 (75.7) 
Exposed and controls were matched by gender and age. 
*Pearson chi²-test from 2×k table. 





Table 2 Functional gastrointestinal disorders in a group of 749 adult patients who had acute giardiasis 






group Unadjusted Adjusted† 
N    n (%) n (%) RR (95% CI) RR  (95% CI) 
IBS 1749 339 (47.9) 149 (14.3) 3.4 (2.8–4.0) 3.4 (3.0–3.8) 
Functional dyspepsia 1779 189 (25.9) 72   (6.9) 3.8 (2.9–4.9) 3.9 (3.1–4.8) 
Bloating 1762 498 (70.0) 417 (39.7) 1.8 (1.6–1.9) 1.8 (1.7–1.9) 
Severe bloating 1762 272 (38.3) 126 (12.0) 3.2 (2.6–3.9) 3.2 (2.7–3.7) 
Diarrhea 1760 100 (14.0) 35   (3.3) 4.2 (2.9–6.1) 4.4 (3.0–6.1) 
Constipation 1761 22   (3.1) 47   (4.5) 0.7 (0.4–1.1) 0.7 (0.4–1.2) 
Nausea 1763 59   (8.3) 30   (2.9) 2.9 (1.9–4.4) 3.0 (2.0–4.7) 
Foul smell 1759 103 (14.5) 38   (3.6) 4.0 (2.8–5.7) 4.1 (2.9–5.7) 
*Number available for analyses differs for different diagnoses due to missing data. 
†Adjusted for gender, age, marital status, educational level, employment status and being a student 
during the outbreak, in logistic regression. 





Table 3 Overlap between different functional gastrointestinal disorders and symptoms in 688 patients three years after acute giardiasis, n (%) 
 Total IBS FD Bloating Diarrhea Constipation Nausea Foul smell 
IBS 331 (100) - 144 (44) 305 (92) 71 (21) 15 (5) 49 (15) 77 (23) 
FD 170 (100) 144 (85) - 160 (94) 54 (29) 9 (5) 37 (22) 62 (36) 
Bloating 481 (100) 305 (63) 160 (33) - 83 (17) 21 (4) 51 (11) 96 (20) 
Diarrhea 95 (100) 71 (75) 49 (52) 83 (87) - 2 (2) 16 (17) 39 (41) 
Constipation 22 (100) 15 (68) 9 (41) 21 (95) 2   (9) - 5 (23) 4 (18) 
Nausea 56 (100) 49 (88) 37 (66) 51 (91) 16 (29) 5 (9) - 27 (48) 
Foul smell 99 (100) 77 (78) 62 (63) 96 (97) 39 (39) 4 (4) 27 (27) - 






Table 4 Overlap between different functional gastrointestinal disorders and symptoms in 1026 controls without previous giardiasis, n (%) 
 Total IBS FD Bloating Diarrhea Constipation Nausea Foul smell 
IBS 146 (100) - 43 (29) 117 (80) 17 (12) 13   (9) 14 (10) 15 (10) 
FD 69 (100) 43 (62) - 6 (81) 13 (19) 8 (12) 11 (16) 11 (16) 
Bloating 403 (100) 117 (29) 56 (14) - 27   (7) 33   (8) 26   (6) 30   (7) 
Diarrhea 33 (100) 17 (52) 13 (39) 27 (82) - 1   (3) 4 (12) 8 (24) 
Constipation 46 (100) 13 (28) 8 (17) 33 (72) 1   (2) - 2   (4) 1   (2) 
Nausea 30 (100) 14 (47) 11 (37) 26 (87) 4 (13) 2   (7) - 6 (20) 
Foul smell 36 (100) 15 (42) 11 (31) 30 (83) 8 (22) 1   (3) 6 (17) - 







Table 5 Irritable bowel syndrome (IBS) subtyping according to Rome III criteria (based on 
stool consistency) and based on frequency of bowel movements (at least sometimes) among 




N = 339 
Control-group 
N = 149 
p value* Criteria  n (%) n (%) 
Stool consistency 
Loose stools 287 (84.7) 104 (69.8) < 0.001 
Hard stools 188 (55.5) 81 (54.4) 0.823 
Rome III subtype 
IBS-D 131 (38.6) 50 (33.6) 
0.001 
IBS-C 32   (9.4) 28 (18.8) 
IBS-M 156 (46.0) 53 (35.6) 
IBS-U 20   (5.9) 18 (12.1) 
Frequency of bowel movements 
Frequent at least sometimes 237 (69.9) 71 (47.7) < 0.001 
Infrequent at least sometimes 47 (13.9) 36 (24.2)   0.005 
Alternative subtype 
IBS with frequent bowel movements 213 (62.8) 62 (41.6) 
< 0.001 
IBS with infrequent bowel movements 23   (6.8) 27 (18.1) 
IBS with both frequent and infrequent 
       bowel movements 24   (7.1) 9 (6.0) 
IBS without abnormal frequency 
       of bowel movements 79 (23.3) 51 (34.2) 
Abbreviations: IBS-D: IBS with diarrhea. IBS-C: IBS with constipation. IBS-M: Mixed 
IBS. IBS-U: Unsubtyped IBS. 







Table 6 Relationship between irritable bowel syndrome (IBS) subtyped by stool consistency 
according to Rome III criteria and IBS subtyped by frequency of bowel movements (at least 
“sometimes”) among 339 patients who fulfilled Rome III criteria for IBS three years after 





















IBS-D 102 (78) 3   (2) 5   (4) 21 (16) 131 (100) 
IBS-C 8 (25) 11 (34) 4 (13) 9 (28) 32 (100) 
IBS-M 96 (62) 8   (5) 15 (10) 37 (24) 156 (100) 
IBS-U 7 (35) 1   (5) 0   (0) 12 (60) 21 (100) 
Total 213 (63) 23   (7) 24   (7) 79 (23) 339 (100) 
Abbreviations: IBS-D: IBS with diarrhea. IBS-C: IBS with constipation. IBS-M: Mixed IBS. 
IBS-U: Unsubtyped IBS. 







Table 7 Relationship between irritable bowel syndrome (IBS) subtyped by stool consistency 
according to Rome III criteria and IBS subtyped by frequency of bowel movements (at least 





















IBS-D 35 (70) 1   (2) 1   (2) 13 (26) 50 (100) 
IBS-C 9 (32) 11 (39) 0   (0) 8 (29) 28 (100) 
IBS-M 14 (26) 13 (25) 8 (15) 18 (34) 53 (100) 
IBS-U 4 (22) 2 (11) 0   (0) 12 (67) 180 (100) 
Total 62 (42) 27 (18) 9   (6) 51 (34) 149 (100) 
Abbreviations: IBS-D: IBS with diarrhea. IBS-C: IBS with constipation. IBS-M: Mixed IBS. 
IBS-U: Unsubtyped IBS. 







Table 8 Relationship between irritable bowel syndrome (IBS) subtyped by Rome III 
criteria and Rome II criteria among 339 patients who fulfilled Rome III criteria for IBS 
three years after acute giardiasis, n (%) 
Rome III Rome II d-IBS Rome II d-IBS Rome II a-IBS Total 
IBS-C 128 (98) 0   (0) 3   (2) 131 (100) 
IBS-C 0   (0) 24 (75) 8 (25) 32 (100) 
IBS-M/U 7   (4) 9   (5) 160 (91) 176 (100) 
Total 135 (40) 33 (10) 171 (50) 339 (100) 
Abbreviations: IBS-D: IBS with diarrhea. IBS-C: IBS with constipation. IBS-M/U: Mixed 
IBS. d-IBS: Diarrhea predominant IBS. c-IBS: Constipation predominant IBS. a-IBS: 
Alternating IBS. 







Table 9 Relationship between irritable bowel syndrome (IBS) subtyped by Rome III 
criteria and Rome II criteria among 149 controls who fulfilled Rome III criteria for IBS, 
n (%) 
Rome III Rome II d-IBS Rome II d-IBS Rome II a-IBS Total 
IBS-C 49 (98) 0   (0) 1   (2) 50 (100) 
IBS-C 0   (0) 19 (68) 9 (32) 28 (100) 
IBS-M/U 4   (6) 14 (20) 53 (75) 71 (100) 
Total 53 (36) 33 (22) 63 (42) 149 (100) 
Abbreviations: IBS-D: IBS with diarrhea. IBS-C: IBS with constipation. IBS-M/U: Mixed 
IBS. d-IBS: Diarrhea predominant IBS. c-IBS: Constipation predominant IBS. a-IBS: 
Alternating IBS. 
Concordance rate: 81.2%. κ = 0.71 (95% CI: 0.61–0.80). 
 
